Clinical Trial

Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial

Study acronym: ECHO-HD

Not Yet Recruiting

Summary

The goal of this clinical trial is to compare a chlorhexidine antimicrobial barrier cap in patients requiring hemodialysis treatment to the standard hemodialysis caps currently used within the Metro North Kidney Health Service. The main questions to answer are: * Study Feasibility * Occurrence of infectious complications related to renal central venous catheters Participants will be randomly allocated to receive either of the below hemodialysis caps to cover their hemodialysis catheter hub: * The standard hemodialysis cap used at the Royal Brisbane and Women's Hospital, or * The intervention hemodialysis cap containing chlorhexidine inside it Researchers will compare standard and chlorhexidine hemodialysis caps to see if the presence of chlorhexidine improves the occurrance of infectious complications related to the hemodialysis catheter.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-06-10; most recent amendment 2026-04-27.

Trial Details

NCT Number	NCT07019610
Lead Sponsor	The University of Queensland Collaborators: Royal Brisbane and Women's Hospital
Conditions	Vascular Access Complication, Device Related Infection, Device Related Sepsis, Catheter Infection, Catheter Complications, Catheter-Related Infections, Catheter Related Complications, Hemodialysis Catheter Infection +2 more
Enrollment	60 participants
Start Date	2026-06
Primary Completion	2027-12 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2026-04-29